Immunogen Inc. | Key People and Executives
Mark J. Enyedy
President, Chief Executive Officer & Director
Stephen C. McCluski
Chairman
Stuart A. Arbuckle
Independent Director
Dean Jonathan Mitchell
Independent Director
Kristine Peterson
Independent Director
Mark Alan Goldberg
Independent Director
Richard J. Wallace
Independent Director
Mark J. Enyedy
President, Chief Executive Officer & Director
David B. Johnston
Chief Financial Officer & Executive Vice President
Richard J. Gregory
Chief Scientific Officer & EVP-Research
Anna Berkenblit
Chief Medical Officer & Vice President
Robert Lutz
VP-Translational Research & Development
Blaine H. McKee
Chief Business Officer & Executive Vice President
Thomas Ryll
Vice President-Technical Operations
Sarah Kiely
Investor Relation Contact
Audrey Bergan
Executive Director-Human Resources
Craig Barrows
Secretary, Executive VP & General Counsel
Theresa G. Wingrove
Senior Vice President-Regulatory Affairs & Quality
Stephen C. McCluski
Chairman
Stuart A. Arbuckle
Independent Director
Dean Jonathan Mitchell
Independent Director
Kristine Peterson
Independent Director
Mark Alan Goldberg
Independent Director
Richard J. Wallace
Independent Director
| Address |
830 Winter Street
Waltham Massachusetts 02451
United States
|
|
Employees
|
- |
| Website |
http://www.immunogen.com |
| Updated |
07/08/2019 |
| ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779, and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA. |
